Previously disclosed buy-backs 0 n.a. n.a.

on November 14, 2024 at 6:00 pm Dubai time / 3:00 pm Oslo time. Dial-in details for the call are included in the press release posted on November 6, 2024 and on page 2 of this release.

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people ...

Scientific progress in ACLF to be featured at The Liver Meeting® 2024, with 4 posters presenting new preclinical data, and 3 events bringing together key ACLF stakeholders Results from UNVEIL-IT® ...

556,500 shares in the Company, by way of donation/gift of 100% of the share capital in Sea Shell Enterprises Limited to members of his family. Following the transactions, Themistoklis Alafouzos will ...

ABIVAX / Key word(s): Personnel Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax 13.11.2024 / 22:01 CET/CEST The issuer is solely responsible for ...

insiders in the Company was incorrect. Please see updated version below.

- Svein Oskar Stoknes has acquired 1,400 shares. Mr. Stoknes' total shareholding in Aker after the acquisition will be 11,400 shares. - Lene Landøy has acquired 1,000 shares. Mrs. Landøy's total ...

service with the Company. In order to settle the RSUs, the Company's board of directors has resolved to issue a total of 155,771 new common shares, each with a par value of USD 0.01. Following the ...

issue of between 107,382,966 to 150,000,000 new shares in the Company, (the "Rights Issue"), of which an underwriting consortium (jointly the "Underwriters") agreed to underwrite subscription of new ...

shareholders, at a fixed subscription price of NOK 3 per New Share (the "Private ...

3:00 pm Oslo time. Dial-in details for the call are included in the press release posted on November 6, 2024 and on page 3 of this release.